Tracleer 125mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Bosentan monohydrate

Available from:

Actelion Pharmaceuticals UK Ltd

ATC code:

C02KX01

INN (International Name):

Bosentan monohydrate

Dosage:

125mg

Pharmaceutical form:

Tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02050100; GTIN: 7640111930037

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
TRACLEER 125 MG FILM-COATED TABLETS
Bosentan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, please ask your doctor or
pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet.
WHAT IS IN THIS LEAFLET
1.
What Tracleer is and what it is used for
2.
What you need to know before you take Tracleer
3.
How to take Tracleer
4.
Possible side effects
5.
How to store Tracleer
6.
Contents of the pack and other information
1.
WHAT TRACLEER IS AND WHAT IT IS USED FOR
Tracleer tablets contain bosentan, which blocks a naturally occurring
hormone called endothelin-1
(ET-1), which causes blood vessels to narrow. Tracleer therefore
causes blood vessels to expand and
belongs to the class of medicines called “endothelin receptor
antagonists”.
Tracleer is used to treat:

PULMONARY ARTERIAL HYPERTENSION (PAH): PAH is a disease of severe
narrowing of the blood
vessels in the lungs resulting in high blood pressure in the blood
vessels (the pulmonary
arteries) that carry blood from the heart to the lungs. This pressure
reduces the amount of
oxygen that can get into the blood in the lungs, making physical
activity more difficult.
Tracleer widens the pulmonary arteries, making it easier for the heart
to pump blood through
them. This lowers the blood pressure and relieves the symptoms.
Tracleer is used to treat patients with class III PAH to improve
exercise capacity (the ability to carry
out physical activity) and symptoms. The ‘class’ reflects the
seriousness of the disease: ‘class III’
involves marked limitation of physical activity. Some improvements
have also been shown in patients
w

Summary of Product characteristics

OBJECT 1
TRACLEER (BOSENTAN) 62.5 MG FILM-COATED TABLETS
Summary of Product Characteristics Updated 01-Dec-2017 | Actelion
Pharmaceuticals UK Ltd
1. Name of the medicinal product
Tracleer 62.5 mg film-coated tablets
Tracleer 125 mg film-coated tablets
2. Qualitative and quantitative composition
Tracleer 62.5 mg film-coated tablets
Each film-coated tablet contains 62.5 mg bosentan (as monohydrate).
Tracleer 125 mg film-coated tablets
Each film-coated tablet contains 125 mg bosentan (as monohydrate).
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet (tablets):
Tracleer 62.5 mg film-coated tablets
Orange-white, round, biconvex, film-coated tablets, embossed with
“62,5” on one side.
Tracleer 125 mg film-coated tablets
Orange-white, oval, biconvex, film-coated tablets, embossed with
“125” on one side.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of pulmonary arterial hypertension (PAH) to improve exercise
capacity and symptoms in
patients with WHO functional class III. Efficacy has been shown in:
• Primary (idiopathic and heritable) pulmonary arterial hypertension
• Pulmonary arterial hypertension secondary to scleroderma without
significant interstitial pulmonary
disease
• Pulmonary arterial hypertension associated with congenital
systemic-to-pulmonary shunts and
Eisenmenger's physiology
Some improvements have also been shown in patients with pulmonary
arterial hypertension WHO
functional class II (see section 5.1).
Tracleer is also indicated to reduce the number of new digital ulcers
in patients with systemic sclerosis
and ongoing digital ulcer disease (see section 5.1).
4.2 Posology and method of administration
Method of administration
Tablets are to be taken orally morning and evening, with or without
food. The film-coated tablets are to
be swallowed with water.
Patients should be advised not to swallow the desiccant found in the
white high-density polyethylene
bottles.
Posology
Pulmonary arterial hypertension
Treatment should only be initiat